Cargando…
Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells
Recent evidence suggest that a β-glucan derived from mushroom Schizophyllan(SPG) complexed with a humanized TLR9 agonistic CpG DNA, K3 (K3-SPG) is a promising vaccine adjuvant that induces robust CD8 T cell responses to co-administered antigen. However, it has not been investigated whether K3-SPG al...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226476/ https://www.ncbi.nlm.nih.gov/pubmed/27384490 http://dx.doi.org/10.18632/oncotarget.10379 |
_version_ | 1782493647543992320 |
---|---|
author | Kitahata, Yuji Kanuma, Tomohiro Hayashi, Masayuki Kobayashi, Nobuyoshi Ozasa, Koji Kusakabe, Takato Temizoz, Burcu Kuroda, Etsushi Yamaue, Hiroki Coban, Cevayir Yamamoto, Takuya Kobiyama, Kouji Aoshi, Taiki Ishii, Ken J. |
author_facet | Kitahata, Yuji Kanuma, Tomohiro Hayashi, Masayuki Kobayashi, Nobuyoshi Ozasa, Koji Kusakabe, Takato Temizoz, Burcu Kuroda, Etsushi Yamaue, Hiroki Coban, Cevayir Yamamoto, Takuya Kobiyama, Kouji Aoshi, Taiki Ishii, Ken J. |
author_sort | Kitahata, Yuji |
collection | PubMed |
description | Recent evidence suggest that a β-glucan derived from mushroom Schizophyllan(SPG) complexed with a humanized TLR9 agonistic CpG DNA, K3 (K3-SPG) is a promising vaccine adjuvant that induces robust CD8 T cell responses to co-administered antigen. However, it has not been investigated whether K3-SPG alone can act as an anti-cancer immunotherapeutic agent or not. Here, we demonstrate that intravenous injection of K3-SPG, but not CpG alone, is accumulated in the tumor microenvironment and triggered immunogenic cell death (ICD) of tumor cells by local induction of type-I interferon (IFN) as well as IL-12. Resultant innate immune activation as well as subsequent tumor-specific CD8 T cell responses were contributed the tumor growth suppression. This anti-tumor effect of K3-SPG monotherapy was also confirmed by using various tumor models including pancreatic cancer peritoneal dissemination model. Taken together, nano-particulate TLR9 agonist injected intravenously can scout out tumor microenvironment to provoke local innate immune activation and release dead tumor cells into circulation that may induce broader and protective tumor antigen-specific CD8 T cells. |
format | Online Article Text |
id | pubmed-5226476 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-52264762017-01-18 Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells Kitahata, Yuji Kanuma, Tomohiro Hayashi, Masayuki Kobayashi, Nobuyoshi Ozasa, Koji Kusakabe, Takato Temizoz, Burcu Kuroda, Etsushi Yamaue, Hiroki Coban, Cevayir Yamamoto, Takuya Kobiyama, Kouji Aoshi, Taiki Ishii, Ken J. Oncotarget Priority Research Paper Recent evidence suggest that a β-glucan derived from mushroom Schizophyllan(SPG) complexed with a humanized TLR9 agonistic CpG DNA, K3 (K3-SPG) is a promising vaccine adjuvant that induces robust CD8 T cell responses to co-administered antigen. However, it has not been investigated whether K3-SPG alone can act as an anti-cancer immunotherapeutic agent or not. Here, we demonstrate that intravenous injection of K3-SPG, but not CpG alone, is accumulated in the tumor microenvironment and triggered immunogenic cell death (ICD) of tumor cells by local induction of type-I interferon (IFN) as well as IL-12. Resultant innate immune activation as well as subsequent tumor-specific CD8 T cell responses were contributed the tumor growth suppression. This anti-tumor effect of K3-SPG monotherapy was also confirmed by using various tumor models including pancreatic cancer peritoneal dissemination model. Taken together, nano-particulate TLR9 agonist injected intravenously can scout out tumor microenvironment to provoke local innate immune activation and release dead tumor cells into circulation that may induce broader and protective tumor antigen-specific CD8 T cells. Impact Journals LLC 2016-07-01 /pmc/articles/PMC5226476/ /pubmed/27384490 http://dx.doi.org/10.18632/oncotarget.10379 Text en Copyright: © 2016 Kitahata et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Priority Research Paper Kitahata, Yuji Kanuma, Tomohiro Hayashi, Masayuki Kobayashi, Nobuyoshi Ozasa, Koji Kusakabe, Takato Temizoz, Burcu Kuroda, Etsushi Yamaue, Hiroki Coban, Cevayir Yamamoto, Takuya Kobiyama, Kouji Aoshi, Taiki Ishii, Ken J. Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells |
title | Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells |
title_full | Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells |
title_fullStr | Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells |
title_full_unstemmed | Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells |
title_short | Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells |
title_sort | circulating nano-particulate tlr9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells |
topic | Priority Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226476/ https://www.ncbi.nlm.nih.gov/pubmed/27384490 http://dx.doi.org/10.18632/oncotarget.10379 |
work_keys_str_mv | AT kitahatayuji circulatingnanoparticulatetlr9agonistscoutsouttumormicroenvironmenttoreleaseimmunogenicdeadtumorcells AT kanumatomohiro circulatingnanoparticulatetlr9agonistscoutsouttumormicroenvironmenttoreleaseimmunogenicdeadtumorcells AT hayashimasayuki circulatingnanoparticulatetlr9agonistscoutsouttumormicroenvironmenttoreleaseimmunogenicdeadtumorcells AT kobayashinobuyoshi circulatingnanoparticulatetlr9agonistscoutsouttumormicroenvironmenttoreleaseimmunogenicdeadtumorcells AT ozasakoji circulatingnanoparticulatetlr9agonistscoutsouttumormicroenvironmenttoreleaseimmunogenicdeadtumorcells AT kusakabetakato circulatingnanoparticulatetlr9agonistscoutsouttumormicroenvironmenttoreleaseimmunogenicdeadtumorcells AT temizozburcu circulatingnanoparticulatetlr9agonistscoutsouttumormicroenvironmenttoreleaseimmunogenicdeadtumorcells AT kurodaetsushi circulatingnanoparticulatetlr9agonistscoutsouttumormicroenvironmenttoreleaseimmunogenicdeadtumorcells AT yamauehiroki circulatingnanoparticulatetlr9agonistscoutsouttumormicroenvironmenttoreleaseimmunogenicdeadtumorcells AT cobancevayir circulatingnanoparticulatetlr9agonistscoutsouttumormicroenvironmenttoreleaseimmunogenicdeadtumorcells AT yamamototakuya circulatingnanoparticulatetlr9agonistscoutsouttumormicroenvironmenttoreleaseimmunogenicdeadtumorcells AT kobiyamakouji circulatingnanoparticulatetlr9agonistscoutsouttumormicroenvironmenttoreleaseimmunogenicdeadtumorcells AT aoshitaiki circulatingnanoparticulatetlr9agonistscoutsouttumormicroenvironmenttoreleaseimmunogenicdeadtumorcells AT ishiikenj circulatingnanoparticulatetlr9agonistscoutsouttumormicroenvironmenttoreleaseimmunogenicdeadtumorcells |